BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 34663800)

  • 1. Oridonin inhibits DNMT3A R882 mutation-driven clonal hematopoiesis and leukemia by inducing apoptosis and necroptosis.
    Liao M; Dong Q; Chen R; Xu L; Jiang Y; Guo Z; Xiao M; He W; Cao C; Hu R; Sun W; Jiang H; Wang J
    Cell Death Discov; 2021 Oct; 7(1):297. PubMed ID: 34663800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling.
    Guryanova OA; Shank K; Spitzer B; Luciani L; Koche RP; Garrett-Bakelman FE; Ganzel C; Durham BH; Mohanty A; Hoermann G; Rivera SA; Chramiec AG; Pronier E; Bastian L; Keller MD; Tovbin D; Loizou E; Weinstein AR; Gonzalez AR; Lieu YK; Rowe JM; Pastore F; McKenney AS; Krivtsov AV; Sperr WR; Cross JR; Mason CE; Tallman MS; Arcila ME; Abdel-Wahab O; Armstrong SA; Kubicek S; Staber PB; Gönen M; Paietta EM; Melnick AM; Nimer SD; Mukherjee S; Levine RL
    Nat Med; 2016 Dec; 22(12):1488-1495. PubMed ID: 27841873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CALCRL knockdown suppresses cancer stemness and chemoresistance in acute myeloid leukemia with FLT3-ITD and DNM3TA-R882 double mutations.
    Tang S; Zhu H; Sheng L; Mu Q; Wang Y; Xu K; Zhou M; Xu Z; Wu A; Ouyang G
    Drug Dev Res; 2024 Feb; 85(1):e22137. PubMed ID: 38349260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response.
    Scheller M; Ludwig AK; Göllner S; Rohde C; Krämer S; Stäble S; Janssen M; Müller JA; He L; Bäumer N; Arnold C; Gerß J; Schönung M; Thiede C; Niederwieser C; Niederwieser D; Serve H; Berdel WE; Thiem U; Hemmerling I; Leuschner F; Plass C; Schlesner M; Zaugg J; Milsom MD; Trumpp A; Pabst C; Lipka DB; Müller-Tidow C
    Nat Cancer; 2021 May; 2(5):527-544. PubMed ID: 35122024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutational analysis of DNMT3A improves the prognostic stratification of patients with acute myeloid leukemia.
    Wakita S; Marumo A; Morita K; Kako S; Toya T; Najima Y; Doki N; Kanda J; Kuroda J; Mori S; Satake A; Usuki K; Ueki T; Uoshima N; Kobayashi Y; Kawata E; Nakayama K; Nagao Y; Shono K; Shibusawa M; Tadokoro J; Hagihara M; Uchiyama H; Uchida N; Kubota Y; Kimura S; Nagoshi H; Ichinohe T; Kurosawa S; Motomura S; Hashimoto A; Muto H; Sato E; Ogata M; Mitsuhashi K; Ando J; Tashiro H; Sakaguchi M; Yui S; Arai K; Kitano T; Miyata M; Arai H; Kanda M; Itabashi K; Fukuda T; Kanda Y; Yamaguchi H
    Cancer Sci; 2023 Apr; 114(4):1297-1308. PubMed ID: 36610002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FLT3-ITD with DNMT3A R882 double mutation is a poor prognostic factor in Chinese patients with acute myeloid leukemia after chemotherapy or allogeneic hematopoietic stem cell transplantation.
    Tang S; Shen H; Mao X; Dai H; Zhu X; Xue S; Ding Z; Lu J; Wu D; Tang X
    Int J Hematol; 2017 Oct; 106(4):552-561. PubMed ID: 28616699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aging-elevated inflammation promotes DNMT3A R878H-driven clonal hematopoiesis.
    Liao M; Chen R; Yang Y; He H; Xu L; Jiang Y; Guo Z; He W; Jiang H; Wang J
    Acta Pharm Sin B; 2022 Feb; 12(2):678-691. PubMed ID: 35256939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of DNMT3A R882 mutations on AML prognosis determined by the allele ratio in Chinese patients.
    Yuan XQ; Chen P; Du YX; Zhu KW; Zhang DY; Yan H; Liu H; Liu YL; Cao S; Zhou G; Zeng H; Chen SP; Zhao XL; Yang J; Zeng WJ; Chen XP
    J Transl Med; 2019 Jul; 17(1):220. PubMed ID: 31291961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent DNMT3A R882 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.
    Lin J; Yao DM; Qian J; Chen Q; Qian W; Li Y; Yang J; Wang CZ; Chai HY; Qian Z; Xiao GF; Xu WR
    PLoS One; 2011; 6(10):e26906. PubMed ID: 22066015
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Jawad M; Afkhami M; Ding Y; Zhang X; Li P; Young K; Xu ML; Cui W; Zhao Y; Halene S; Al-Kali A; Viswanatha D; Chen D; He R; Zheng G
    Front Oncol; 2022; 12():849376. PubMed ID: 35296003
    [No Abstract]   [Full Text] [Related]  

  • 11. Identification of Cell Type-Specific Effects of
    Bae SG; Kim HJ; Kim MY; Kim DDH; Shin SI; Ahn JS; Park J
    Mol Cells; 2023 Oct; 46(10):611-626. PubMed ID: 37853686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNMT3A R882 Mutations Predict a Poor Prognosis in AML: A Meta-Analysis From 4474 Patients.
    Yuan XQ; Peng L; Zeng WJ; Jiang BY; Li GC; Chen XP
    Medicine (Baltimore); 2016 May; 95(18):e3519. PubMed ID: 27149454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene expression profiling of the DNMT3A R882 mutation in acute leukemia.
    Huang X; Ma D; Dong W; Li P; Lu T; He N; Tian T; Liu N; DU Y; Ji C
    Oncol Lett; 2013 Jul; 6(1):268-274. PubMed ID: 23946816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation.
    Ahn JS; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):61-70. PubMed ID: 26234722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia.
    Bhatnagar B; Eisfeld AK; Nicolet D; Mrózek K; Blachly JS; Orwick S; Lucas DM; Kohlschmidt J; Blum W; Kolitz JE; Stone RM; Bloomfield CD; Byrd JC
    Br J Haematol; 2016 Oct; 175(2):226-236. PubMed ID: 27476855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of FLT3-ITD with DNMT3A R882 double-mutation on the prognosis of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
    Tang SH; Lu Y; Zhang PS; Liu XH; Du XH; Chen D; Sha KY; Li SY; Cao JJ; Chen LG; Zhuang XX; Pei RZ; Tang XW
    Zhonghua Xue Ye Xue Za Zhi; 2018 Jul; 39(7):552-557. PubMed ID: 30122013
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical Features and MicroRNA Expression Patterns Between AML Patients With DNMT3A R882 and Frameshift Mutations.
    Yang L; Shen K; Zhang M; Zhang W; Cai H; Lin L; Long X; Xing S; Tang Y; Xiong J; Wang J; Li D; Zhou J; Xiao M
    Front Oncol; 2019; 9():1133. PubMed ID: 31709191
    [No Abstract]   [Full Text] [Related]  

  • 18. DNMT3A R882H mutation drives daunorubicin resistance in acute myeloid leukemia via regulating NRF2/NQO1 pathway.
    Chu X; Zhong L; Dan W; Wang X; Zhang Z; Liu Z; Lu Y; Shao X; Zhou Z; Chen S; Liu B
    Cell Commun Signal; 2022 Oct; 20(1):168. PubMed ID: 36303144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical Value of Translocator Protein Gene in Evaluating the Efficacy of
    Tang SH; Lu Y; Zhang PS; Chen D; Liu XH; DU XH; Cao JJ; Li SY; Sha KY; Chen LG; Zhuang XX; Ye PP; Lin L; Pei RZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Feb; 31(1):45-49. PubMed ID: 36765475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metformin reduces the clonal fitness of
    Hosseini M; Voisin V; Chegini A; Varesi A; Cathelin S; Ayyathan DM; Liu ACH; Yang Y; Wang V; Maher A; Grignano E; Reisz JA; D'Alessandro A; Young K; Wu Y; Fiumara M; Ferrari S; Naldini L; Gaiti F; Pai S; Schimmer AD; Bader GD; Dick JE; Xie SZ; Trowbridge JJ; Chan SM
    Res Sq; 2024 Feb; ():. PubMed ID: 38405837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.